Andrea Necchi

32.5k total citations · 9 hit papers
585 papers, 12.3k citations indexed

About

Andrea Necchi is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrea Necchi has authored 585 papers receiving a total of 12.3k indexed citations (citations by other indexed papers that have themselves been cited), including 518 papers in Surgery, 237 papers in Oncology and 168 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrea Necchi's work include Bladder and Urothelial Cancer Treatments (369 papers), Urinary and Genital Oncology Studies (205 papers) and Cancer Immunotherapy and Biomarkers (179 papers). Andrea Necchi is often cited by papers focused on Bladder and Urothelial Cancer Treatments (369 papers), Urinary and Genital Oncology Studies (205 papers) and Cancer Immunotherapy and Biomarkers (179 papers). Andrea Necchi collaborates with scholars based in Italy, United States and France. Andrea Necchi's co-authors include Joaquim Bellmunt, Daniel P. Petrylak, Dean F. Bajorin, Toni K. Choueiri, David I. Quinn, Cora N. Sternberg, Daniele Raggi, Nicholas J. Vogelzang, Ronald de Wit and Lawrence Fong and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Andrea Necchi

542 papers receiving 12.2k citations

Hit Papers

Pembrolizumab as Second-Line Therapy for Advanced Urothel... 2014 2026 2018 2022 2017 2017 2014 2021 2019 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    2017 2.4k citations Ronald de Wit, Miguel Ángel Climent et al. profile →
  2. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
    2017 1.2k citations Padmanee Sharma, Arlene O. Siefker‐Radtke et al. profile →
  3. EAU Guidelines on Penile Cancer: 2014 Update
    2014 414 citations Andrea Necchi et al. European Urology profile →
  4. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2021 309 citations Maria De Santis, Yohann Loriot et al. profile →
  5. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
    2019 306 citations Andrea Necchi, Howard Gurney et al. profile →
  6. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors
    2023 222 citations Ashish M. Kamat, Joshua J. Meeks et al. European Urology profile →
  7. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
    2021 175 citations Michiel S. van der Heijden, Yohann Loriot et al. profile →
  8. Penile cancer
    2021 133 citations Andrea Necchi, Philippe E. Spiess et al. profile →
  9. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma
    2024 74 citations Thomas Powles, Maria De Santis et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrea Necchi Italy 46 8.9k 5.7k 2.7k 2.1k 1.2k 585 12.3k
Thomas Powles United Kingdom 49 5.3k 0.6× 5.9k 1.0× 2.9k 1.1× 1.9k 0.9× 1.9k 1.6× 338 10.6k
Christine Théodore France 39 3.9k 0.4× 3.5k 0.6× 6.0k 2.2× 2.1k 1.0× 387 0.3× 164 10.5k
Esther Oliva United States 67 2.7k 0.3× 1.9k 0.3× 3.7k 1.4× 3.2k 1.5× 515 0.4× 296 12.9k
Yohann Loriot France 52 4.4k 0.5× 6.2k 1.1× 4.5k 1.7× 2.4k 1.2× 1.5k 1.3× 457 11.9k
Paul Perrotte Canada 60 5.0k 0.6× 3.2k 0.6× 7.7k 2.8× 3.5k 1.7× 420 0.4× 311 12.6k
Jonathan E. Rosenberg United States 51 7.0k 0.8× 5.5k 1.0× 4.1k 1.5× 4.2k 2.1× 1.1k 0.9× 404 13.5k
Lance C. Pagliaro United States 41 2.1k 0.2× 2.1k 0.4× 2.4k 0.9× 1.6k 0.8× 460 0.4× 199 5.9k
Claus Rödel Germany 52 9.7k 1.1× 11.3k 2.0× 3.6k 1.3× 1.8k 0.9× 385 0.3× 261 16.1k
Jae‐Lyun Lee South Korea 47 4.7k 0.5× 6.2k 1.1× 5.2k 1.9× 2.7k 1.3× 1.0k 0.9× 394 11.4k
Sandrine Marréaud Belgium 38 2.7k 0.3× 3.8k 0.7× 4.8k 1.8× 1.6k 0.8× 277 0.2× 145 7.7k

Countries citing papers authored by Andrea Necchi

Since Specialization
Citations

This map shows the geographic impact of Andrea Necchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Necchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Necchi more than expected).

Fields of papers citing papers by Andrea Necchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Necchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Necchi. The network helps show where Andrea Necchi may publish in the future.

Co-authorship network of co-authors of Andrea Necchi

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Necchi. A scholar is included among the top collaborators of Andrea Necchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Necchi. Andrea Necchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pavlick, Dean C., S. Lindsey Davis, Christopher H. Lieu, et al.. (2025). Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study. ESMO Open. 10(6). 105312–105312.
2.
Powles, Thomas, Enrique Grande, Nimira Alimohamed, et al.. (2025). SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma. Future Oncology. 21(21). 2705–2712. 1 indexed citations
3.
Li, Roger, Ashish M. Kamat, Petros Grivas, et al.. (2025). Primary sarcomas of the bladder and prostate: A genomic landscape study. Pathology - Research and Practice. 267. 155840–155840.
4.
5.
Safa, Houssein, et al.. (2024). Overview of Systemic Therapies in Penile Cancer. Urologic Clinics of North America. 51(3). 347–354. 1 indexed citations
6.
Necchi, Andrea, Michiel S. van der Heijden, Avivit Peer, et al.. (2024). Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study. BMC Cancer. 23(S1). 1252–1252. 6 indexed citations
7.
Tateo, Valentina, Scott M. Gilbert, Victoria K. Cortessis, et al.. (2024). Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review. European Urology. 87(4). 427–441. 9 indexed citations
8.
Li, Roger, James W.F. Catto, Siamak Daneshmand, et al.. (2024). FGFR Inhibition in Urothelial Carcinoma. European Urology. 87(2). 110–122. 12 indexed citations
9.
Muro, Xavier García del, D. Páez López-Bravo, Pablo Maroto, et al.. (2024). Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study. European Urology Oncology. 8(2). 278–286. 6 indexed citations
10.
Fallara, Giuseppe, Daniele Robesti, Daniele Raggi, et al.. (2023). Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer. European Urology Open Science. 52. 40–43. 5 indexed citations
11.
Bersanelli, Melissa, Giulia Mazzaschi, Patrizia Giannatempo, et al.. (2021). Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). Immunotherapy. 14(2). 107–114. 2 indexed citations
12.
Curran, Catherine, Elio Adib, Petros Grivas, et al.. (2021). Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin. Clinical Genitourinary Cancer. 20(1). 11–16. 5 indexed citations
13.
Galsky, Matthew D., Christopher Hoimes, Andrea Necchi, et al.. (2021). Perioperative Pembrolizumab Therapy in Muscle-Invasive Bladder Cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncology. 17(24). 3137–3150. 38 indexed citations
14.
15.
Rouanne, Mathieu, Dean F. Bajorin, Raquibul Hannan, et al.. (2020). Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. European Urology Oncology. 3(6). 728–738. 57 indexed citations
16.
Necchi, Andrea, et al.. (2020). Utility of Minimally Invasive Technology for Inguinal Lymph Node Dissection in Penile Cancer. Journal of Clinical Medicine. 9(8). 2501–2501. 8 indexed citations
17.
Aydın, Ahmet Murat, Jad Chahoud, Jacob J. Adashek, et al.. (2020). Understanding genomics and the immune environment of penile cancer to improve therapy. Nature Reviews Urology. 17(10). 555–570. 39 indexed citations
18.
Madison, Russell W., Sumati Gupta, Yasir Y. Elamin, et al.. (2020). Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. British Journal of Urology. 125(5). 739–746. 11 indexed citations
19.
Galsky, Matthew D., Abdel Saci, Péter M. Szabó, et al.. (2020). Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. Clinical Cancer Research. 26(19). 5120–5128. 83 indexed citations
20.
Chahoud, Jad, et al.. (2020). Second line salvage systemic therapy for advanced penile cancer. Urologic Oncology Seminars and Original Investigations. 40(6). 229–234. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Powles Breakdown of academic impact, for papers by Christine Théodore Breakdown of academic impact, for papers by Esther Oliva Breakdown of academic impact, for papers by Yohann Loriot Breakdown of academic impact, for papers by Paul Perrotte Breakdown of academic impact, for papers by Jonathan E. Rosenberg Breakdown of academic impact, for papers by Lance C. Pagliaro Breakdown of academic impact, for papers by Claus Rödel Breakdown of academic impact, for papers by Jae‐Lyun Lee Breakdown of academic impact, for papers by Sandrine Marréaud
Rankless by CCL
2026